This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (26)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Viral Infections  • Transplantation  • Transplantation, Other  • Review  • Immunology  • Immunologic Disorders  • Immunology, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Pietro Andreone, MD; Annagiulia Gramenzi, MD; Stefania Lorenzini, MD; Maurizio Biselli, MD; Carmela Cursaro, MD; Stefano Pileri, MD; Mauro Bernardi, MD

Arch Intern Med. 2003;163:1997-2004.

Posttransplantation lymphoproliferative disorders include a wide spectrum of diseases ranging from hyperplastic-appearing lesions to frank non-Hodgkin lymphoma. More than 90% of these disorders are Epstein-Barr virus–associated lesions of B-cell origin that arise in the setting of pharmacologic immunosuppression after transplantation. With the increased use of organ transplantation and intensive immunosuppression, posttransplantation lymphoproliferative disorders are becoming more common. The prognosis is often poor, with most patients dying despite receiving treatment. The aim of this review is to report the most recent knowledge about the clinical features, diagnosis, prophylaxis, and treatment of posttransplantation lymphoproliferative disorders, which can be useful to physicians and health assistants dealing with these life-threatening, posttransplantation clinical entities in clinical practice.

From the Dipartimento di Medicina Interna, CardioAngiologia ed Epatologia (Drs Andreone, Gramenzi, Lorenzini, Biselli, Cursaro, and Bernardi) and the Istituto di Ematologia ed Oncologia Medica "L e A Seràgnoli" (Dr Pileri), Policlinico S Orsola-Malpighi, Bologna, Italy. Drs Andreone, Gramenzi, Lorenzini, Biselli, Cursaro, and Bernardi are now with the Dipartimento Medicina Interna, CardioAngiologia ed Epatologia, University of Bologna, Italy. Dr Pileri is now with the Istituto di Ematologia ed Oncologia Medica "L e A Seràgnoli," University of Bologna. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle
Sokol and Beaugerie
Gut 2009;58:1427-1436.
ABSTRACT | FULL TEXT  

Diabetes and Risk of Non-Hodgkin's Lymphoma: A meta-analysis of observational studies
Mitri et al.
Diabetes Care 2008;31:2391-2397.
ABSTRACT | FULL TEXT  

EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma
Kluin-Nelemans et al.
Blood 2008;112:1039-1041.
ABSTRACT | FULL TEXT  

Infectious Agents as Causes of Non-Hodgkin Lymphoma
Engels
Cancer Epidemiol. Biomarkers Prev. 2007;16:401-404.
ABSTRACT | FULL TEXT  

Critical Care Perspective on Immunotherapy in Lung Transplantation
Taylor and Palmer
J Intensive Care Med 2006;21:327-344.
ABSTRACT